WOCKPHARMA

Ref. No.: WOCK/SEC/SE/2021-22/136 8th March, 2022 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Dear Sir/Madam, Sub: Investor Presentation. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith for your information a copy of the latest investor presentation of the Company. You are requested to kindly take the same on record. Thanking you, for Wockhardt Limited Debashis Dey Company Secretary Project Liberty Opportunity to invest in US pharma business Investors Presentation 2022 Safe harbor The Wockhardt Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a rights issue of its equity shares and has filed a Letter of Offer. The Letter of Offer is available on the website of the SEBI at https://www.sebi.gov.in, the website of BSE at https://www.bseindia.com, the website of NSE at https://www.nseindia.com, the website of the Lead Manager at www.ambit.co and the website of the registrar to the Issue at www.linkintime.co.in. Investors should note that investment in equity shares involves a high degree of risk. For details, potential investors should refer to the Letter of Offer, includingthe section titled “Risk Factors”.” Strictly confidential | Page 2 Snapshot of Wockhardt Net Sales Revenues INR 2,575 Cr 12 manufacturing facilities across world (9M FY22) EBITDA INR 331 Cr 3 R&D centres one each in India, UK, USA (9M FY22) Profit after tax Over 520 scientists with over 80 PhD’s; INR 32 Cr (9M FY22) Drug Discovery team > 150 associates ~ 5,400 employees3globally with over 20% employees4 Net Debt-Equity Ratio 0.34x1 based outside India International business >80%2 3,214 patents filed; 793 patents granted Pharmaceuticals Vaccines Diabetes Biosimilars Novel Antibiotics & API 1 -9M FY 21-22. Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances 2 -For the year FY 2020-21 3-Includes approximately 1,500 contract employees Strictly confidential | Page 3 4-For the 3,900 employees on payroll of Company Financial highlights Net Sales Revenues in INR Cr. EBITDA in INR Cr. 24% YOY growth 331 2,844 2,708 2,575 245 -47 FY 19-20 FY 20-21 9M FY 21-22 FY 19-20 FY 20-21 9M FY 21-22 PAT (Continued operations) after exceptional items in INR Cr. Reduction in long term debts* in INR Cr. 32 -138 -296 2,045 1,259 1,084 FY 19-20 FY 20-21 9M FY 21-22 Mar-20 Mar-21 Dec-21 *Excluding promoter debt & preference capital Strictly confidential | Page 4 Net Debt : Equity @ 0.34* Total Equity increased by >INR 700 Cr. ; Total Borrowings Reduction by > INR 1,000 Cr. Total Equity INR Cr. Total Borrowings INR Cr.* 3,760 3,774 3,057 2,632 1,853 1,569 FY 19-20 FY 20-21 9M FY 21-22 FY 19-20 FY 20-21 9M FY 21-22 Cash & cash equivalents and other Bank balances INR Cr. Net Debt-Equity Ratio * 292 285 0.77 268 0.42 0.34 FY 19-20 FY 20-21 9M FY 21-22 FY 19-20 FY 20-21 9M FY 21-22 *9M FY 21-22. Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances Strictly confidential | Page 5 Future Growth drivers 5 years growth drivers 1 Novel drug discovery 2 Diabetes Biosimilars in US & Europe 2 years growth drivers 1 Vaccines - Focus on COVID-19 Vaccines 2 Diabetes Biosimilars for Emerging markets 3 Re-organized business structure & leadership Strictly confidential | Page 6 Growth drivers for next 2 years 1 Vaccines - Focus on COVID-19 Vaccines Global CMO Supply to UK Govt. >100 Mn Doses supplied Flexibility of supplies from Fill-finish supply of Astra existing India & UK sites Zeneca / University of Oxford COVID-19 Vaccine to UK Govt. Strictly confidential | Page 7 Growth drivers for next 2 years 2 Diabetes Biosimilars for Emerging markets Focus on Recombinant Human Insulin and Insulin Glargine in emerging markets API + Low cost manufacturing Manufacturing infrastructure ready Formulation > 25 Under registration in 12 Registered in emerging markets countries markets Development Own patented device Integrated end to end capabilities to marketing Strictly confidential | Page 8 Growth drivers for next 2 years: 3 Re-organized business structure & leadership A Renew leadership B Focus markets Emerging UK India USA markets C Wockhardt selected by Indian Government’s Production Linked Incentive (PLI) Scheme Strictly confidential | Page 9 Growth drivers for next 5 years 1 Novel drug discovery – focus on Antibiotics against resistant infections 6 QIDP* grant from US FDA for Wockhardt’s 6 novel antibiotics WCK 5222 (Cephalosporin + β-lactam enhancer) -Destination therapy for XDR Gram Negative Acinetobacter & Pseudomonas Pre-clinical Phase I Phase II1 Global Phase III Followed by C o m p l e t e d Initiated Regulatory filing Planned completion by end of CY20232 *- Qualified Infectious Disease Product (QIDP) status granted by US FDA eligible for fast track development process and priority review. QIDP status also grants five year extension to the market exclusivity in the United States 1.Phase II: Waiver Strictly confidential | Page 10 2.Based on management estimates WCK 5222 differentiation Activity against resistant infection Pipeline Drugs Approved Drugs Organism/ Resistance Mech. WCK Product Product Product Product Product Product Product Product Product 52221 1 2 3 4 5 6 7 8 9 K. pneumoniae (ESβL) K. pneumoniae (KPC) K. pneumoniae (MβL) E. coli (PBP3 insert+ESBL/Class C) MIC v I i n vo E. coli (MβL±PBP3 Insert) MIC v I i n vo Enterobacter(AmpC) Proteus (ESβL, Class C) P. aeruginosa(AmpC + oprD +Efflux) P. aeruginosa (Oxa, oprD + Efflux) P. aeruginosa (MβL) A. baumannii(CHDL, OXA) Most S. maltophiliaMDR/XDR MIC v I i n vo Isolates Resistant Sub-optimal Perfomancefor Most Isolates Susceptible Variable Susceptibility Most Isolates Resistant Strains with MIC ≤ Breakpoint 1.WCK 5222: Cifepime+ Zidebactam` Strictly confidential | Page 11 Novel drug discovery pipeline – focus on Antibiotics against resistant infections Robust product pipeline Development Stage Target market 1 Emrok IV / Emrok O Launched in India Emerging Markets Partnered with 2 WCK 4873 Phase III Emerging Markets Jemincare for Greater China 3 WCK 4282 Phase III Global 4 WCK 6777 Phase I US Strictly confidential | Page 12 Growth drivers for next 5 years 2 Diabetes Biosimilars for US & Europe Biosimilars Portfolio of Insulin & GLP-1 analogs Product Type Development Stage 1 Insulin Glargine Long acting analogue GMP batches for Clinical 2 Insulin Aspart Rapid acting analogue Product developed / Under testing 3 Insulin Lispro Rapid acting analogue Product developed / Under testing 4 Liraglutide GLP-1 analogue Under development Integrated end to end capabilities Limited competition Manufacturing capacity ready from development to marketing Strictly confidential | Page 13 Leadership Team Ravi Limaye Ajay Sahni Dr. Mahesh Patel Managing Director- Wockhardt UK Managing Director -Wockhardt Bio Chief Scientific Officer AG / France / Pinewood Dr. HabilKhorakhiwala Founder and Executive Chairman Prakash Gupta LalitAggarwal Pradnya Deshmukh Dr. VijayeshGupta President-Global Supply Chain President -Manufacturing President –Quality & Compliance President –Global Strategy, Growth Initiatives Renewed Leadership (Joined in last 1 year) Robert Spina Vivek Bachhawat AmrutMedhekar AvijitDeb Dr. MurtazaKhorakhiwala President -North America President -Emerging Markets Head-India Branded Business Chief Digital Officer Managing Director Strictly confidential | Page 14 Board of Directors Mr. AmanMehta Mr. D. S. Brar Dr. SanjayaBaru Independent Director Independent Director Independent Director ► Past Head of HSBC operations in India ► Ex-CEO & MD, Ranbaxy Laboratories ► Ex-Official spokesman PMO ► Over 35 years of experience ► Founder of GVK Biosciences Pvt. Ltd ► Ex-Secretary General, FICCI Dr. HabilKhorakiwala ► Ex-Director, RBI ► Ex-Director, IISS London Founder and Executive Chairman ► Member on Board, NIPER; ► Ex-Chief Editor, The Financial Express ► Ex-Chairman,IndianMNC Council of CII ► Ex-President, FICCI ► Ex-President, IPA Mrs. TasneemMehta Mr. VineshKumar Jairath Mr. AkhileshGupta ► Ex-Chancellor, JHU, New Delhi Independent Director Independent Director Independent Director ► Dr. Bhau Daji Lad Museum, Managing ► Ex-IAS, GoMand GoI ► Ex-Chairman, Blackstone India Trustee and Honorary Director ► Ex-Managing Director, SICOM ► Ex-CEO, Corporate Development, ► Former Vice Chairman & Mumbai ► Ex Principal Secretary of Industries GoM Reliance Industries Limited Convenor, INTACH ► Advisory Council of Graduate School of Business , Stanford University Dr. MurtazaKhorakiwala Managing Director Mrs. Rima Marphatia Dr. HuzaifaKhorakiwala Ms. ZahabiyaKhorakiwala Nominee Director Executive Director Non-Executive Director ► Immediate past President, International Chamber of Commerce (ICC), India ► Ex-President, BMA ► Chief General Manager, Exim bank ► Trustee & CEO, Wockhardt Foundation ► Managing Director, Wockhardt ► Member, Executive Committee, IPA ► Ex-Member of RBI committee on ► Founder, The World Peacekeepers Hospitals financial Institutions ► 13 Honorary Doctorates& a Knighthood ► BOD, RPG Life Sciences Ltd Strictly confidential | Page 15 Abbreviations • API:Active Pharmaceutical Ingredient • CMO: Contract Manufacturing Organization • EBITDA: Earnings before Interest, Tax, DepreciationandAmortization • GLP-1: Glucagon like Peptide-1 • GMP: Good Manufacturing Practice • KOL: Key Opinion Leader • MDR: Multi Drug Resistant • MIC: Minimum InhibitoryConcentration • PAT: ProfitAfterTax • QIDP: QualifiedInfectious Disease Product • US FDA: United States Food & DrugAdministration • XDR: Extremely Drug Resistant Strictly confidential | Page 16 Life wins ! Impacting Life Saving Life Affordability Stakeholders Strictly confidential | Page 17